References
- Karimi M, Jamalian N, Yarmohammadi H, et al. Premarital screening for β-thalassaemia in Southern Iran: options for improving the programme. J Med Screen. 2007;14(2):62–66
- Najmabadi H, Karimi-Nejad R, Sahebjam S, et al. The β-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001;25(3):285–296
- Noori-Daloii MR, Moazami N, Izadyar M. Molecular studies on the distribution of β-thalassaemia in Iran. The basis of prenatal diagnosis. MJIRI. 1994;8(2):101–108
- Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010;24(6):1005–1020
- Vichinsky EP. Changing patterns of thalassemia worldwide. Ann NY Acad Sci. 2005;1054:18–24
- Keskin A, Türk T, Polat A, et al. Premarital screening of β-thalassemia trait in the province of Denizli, Turkey. Acta Haematol. 2000;104(1):31–33
- Cao A, Rosatelli MC, Galanello R. Control of β-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found Symp. 1996;197:137–151; discussion: 151–155
- Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for β-thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18(10):1077–1083
- National guideline for prevention of thalassemia. Ministry of Health and Medical Education. Seda publication, 2004 [Report in Persian]. Available from: http://health.Tums.ac.ir/CMSFiles/file/BIMARIHA/pdf [Last accessed 22 Aug 2013]
- Samavat A, Bemadette M. Iranian national thalassemia screening program. BMJ. 2004;329(7475):1134–1137
- Thalassemia Report 2012 of Deputy for Health of Shiraz University of Medical Sciences [Report in Persian]. Shiraz, Iran: 2012. Available form: http://fhc.sums.ac.ir/files/gh-vagir/thalasemia.pdf [Last accessed 15 Sep 2013]
- Atkin K, Ahmad WIU. Genetic screening and haemoglobinopathies: ethics, politics and practice. Soc Sci Med. 1998;46(3):445–448
- Tarazi I, Al Najjar E, Lulu N, Sirdah M. Obligatory premarital tests for β-thalassaemia in the Gaza Strip: evaluation and recommendations. Int J Lab Hematol. 2007;29(2):111–118
- Acemoglu H, Beyhun NE, Vancelik S, et al. Thalassaemia screening in a non-prevalent region of a prevalent country (Turkey): is it necessary? Public Health. 2008;122(6):620–624
- Al Hamdan NA, Al Mazrou YY, Al Swaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007;9(6):372–377
- Cao A, Furbetta M, Galanello R, et al. Prevention of homozygous β-thalassemia by carrier screening and prenatal diagnosis in Sardinia. Am J Med Genet. 1981;33(4):592–595
- Cao A, Rosatelli MC, Leoni GB, et al. Antenatal diagnosis of β-thalassemia in Sardinia. Ann NY Acad Sci. 1990;612:215–225
- Lena-Russo D, Badens C, Aubinaud M, et al. Outcome of a school screening program for carriers of hemoglobin disease. J Med Screen. 2002;9(2):67–69
- Greengross P, Hickman M, Gill M, et al. Outcomes of universal antenatal screening for haemoglobinopathies. J Med Screen. 1999;6(1):3–10
- Armeli C, Robbins SJ, Eunpu D. Comparing knowledge of β-thalassemia in samples of Italians, Italian-Americans, and non-Italian-Americans. J Genet Couns. 2005;14(4):365–376
- Tsianakas V, Calnan M, Atkin K, et al. Offering antenatal sickle cell and thalassaemia screening to pregnant women in primary care: a qualitative study of GPs’ experiences. Br J Gen Pract. 2010;60(580):822–828
- Ahmed S, Green J, Hewison J. What are Pakistani women’s experiences of antenatal carrier screening for β-thalassaemia in the UK? Why it is difficult to answer this question? Public Health. 2002;116(5):297–299
- Joulaei H, Lankarani KB, Shahbazi M. Iranian and American health professionals working together to address health disparities in Mississippi Delta based on Iran’s Health House Model. Arch Iran Med. 2012;15(6):378–380
- Stephens AD, Angastiniotis M, Baysal E, et al. ICSH recommendations for the measurement of Haemoglobin A2. International Council for the Standardisation of Haematology (ICSH). Int J Lab Hematol. 2012;34(1):1–13